Companies › Livzon Pharmaceutical Group
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 3; Cardiovascular, Gastroenterology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JP-1366 Proton pump inhibitor | – | Phase 3 | Reflux Esophagitis (RE) | – |
| H001 Capsule | – | Phase 2 | Circulatory Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06850480 | JP-1366 | Phase 3 | Reflux Esophagitis (RE) | Gastroenterology | Apr 2025 |
| NCT06963320 | H001 Capsule | Phase 2 | Circulatory Disease | Cardiovascular | Jun 2025 |
No annotated target.
–
Matrix Biomed Shin Poong Pharmaceutical Noorik Biopharmaceuticals Getz Pharma Beijing Continent Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.